mass-spectrometry
(13)
Virtue Diagnostics
Virtue Diagnostics is a platform-based in vitro diagnostics (IVD) company headquartered in Singapore, with manufacturing in Suzhou, China and clinical operations in Beijing. Founded in 2019, it develops affordable diagnostic instruments and reagents across chemiluminescence, clinical chemistry, hematology, clinical mass spectrometry, multiplex immunohistochemistry (mIHC) and molecular diagnostics, aiming to serve patients through every stage of disease - from early screening and diagnosis to treatment monitoring and minimal residual disease management. Its strategy centers on localized innovation and expansion in emerging markets including China, Singapore, Brazil, Indonesia and the Philippines. The company closed a US$100 million Series B round in January 2022 led by Sequoia China and Morningside Ventures.
Antares Therapeutics
Antares Therapeutics is a Boston-based biotechnology company that discovers small-molecule precision medicines against historically 'undruggable' targets in cancer and other serious diseases. Spun out of Scorpion Therapeutics in June 2025 with $177 million in Series A financing, Antares combines proprietary compound libraries, next-generation mass spectrometry, chemical proteomics, and machine-learning-driven computational chemistry to find new binding pockets on proteins - such as transcription factors - that were long considered impossible to drug. Its lead program is slated to enter the clinic in 2026, and the company signed a collaboration worth up to $1.9 billion with Novartis in mid-2026.
Enveda
Enveda is a clinical-stage biotech that uses artificial intelligence to read the chemistry of the natural world and turn it into new medicines. Founded in 2019 by Viswa Colluru, the company built PRISM, a foundation model trained on more than a billion mass spectra, to decode the structure of natural molecules that traditional methods leave invisible. That platform has produced a pipeline of small-molecule drug candidates - led by ENV-294, an oral anti-inflammatory now in Phase 2 trials for atopic dermatitis and asthma. Backed by more than $700M in funding and valued as a unicorn, Enveda operates out of Boulder, Colorado and Hyderabad, India.
Talus Bio
Talus Bio is a Seattle drug-discovery company going after transcription factors and other regulatory proteins long written off as 'undruggable.' Its MARMOT platform measures the human regulome directly in living cells using functional proteomics and high-throughput mass spectrometry, then feeds tens of millions of compound-target interactions into a lab-in-the-loop AI system to design small molecules that switch disease-driving genes on or off. Founded in 2020 by Alex Federation and Lindsay Pino, the company runs preclinical programs in chordoma, non-small cell lung cancer, and prostate cancer.
InterVenn Biosciences
InterVenn Biosciences is a South San Francisco biotech building an AI-driven glycoproteomics platform that reads the sugar coatings on proteins to detect disease earlier. Its flagship blood test, GlycoKnow Ovarian, distinguishes ovarian cancer from benign pelvic masses with ~86% accuracy and went commercial in 2025. Founded in 2017 by Aldo Carrascoso with chemists Carolyn Bertozzi (Nobel Laureate) and Carlito Lebrilla, the company has raised roughly $244M, including a $201M Series C led by SoftBank in 2021.
Alex Federation
Alex Federation is the co-founder and CEO of Talus Bio, a Seattle biotech building drugs for transcription factors, the gene-control proteins long written off as 'undruggable.' A Harvard-trained chemical biologist who studied under Jay Bradner, he invented the MARMOT platform to measure and modulate the regulome inside living cells, pairing functional proteomics with AI models trained on tens of millions of compound-target interactions. He teamed with proteomics scientist Lindsay Pino in 2020, went through Y Combinator, and has raised roughly $24.7M to chase first-in-class medicines for targets like Brachyury, AR-V7, and STAT3.
Daojing Wang
Daojing Wang is the founder, president, and CEO of Newomics, a Berkeley biotech building chip-based mass spectrometry tools for precision medicine. A Princeton-trained chemist who spent 11 years as a principal investigator at Lawrence Berkeley National Laboratory, he co-invented the M3 emitter and multinozzle emitter array (MEA) - a silicon shower-head that makes mass spectrometers far more sensitive. He spun the technology out of the national lab in 2013 and has since shipped well over 100 systems to labs worldwide.
Matterworks
Matterworks is a Somerville, Massachusetts biotech-AI company building foundation models for molecular biology. Its Large Spectral Models (LSMs) are trained on billions of mass spectrometry spectra and read raw molecular signals directly, turning slow, manual mass-spec workflows into automated, untargeted absolute quantitation. Its flagship cloud platform, Pyxis, acts as a predictive omics assistant that converts raw LC-MS data into identified, quantified molecules and biological insight - making mass spectrometry usable by any biologist rather than only specialist analysts.
Newomics, Inc.
Newomics is a Berkeley, California biotechnology company building mass spectrometry front-end hardware for precision medicine. Spun out of Lawrence Berkeley National Laboratory, its silicon multinozzle emitter (M3) and MnESI ion source upgrade existing mass spectrometers to deliver microflow robustness with nanospray sensitivity, enabling higher-throughput, higher-sensitivity multiomics across proteomics, metabolomics, lipidomics, native MS and single-cell analysis. The company sells to pharmaceutical, academic and government labs and co-markets with major instrument vendors like Thermo Fisher Scientific.
Jack Geremia
Jack Geremia is the CEO and co-founder of Matterworks, a Somerville, Massachusetts biotech building Large Spectral Models - foundation models that read raw mass spectrometry signals the way a large language model reads text. A Princeton-trained chemist and former Caltech quantum-control postdoc turned serial biotech founder, he has spent 25-plus years moving technologies from lab bench to market, authoring more than 100 patents and publications. After co-founding Matterworks in 2019 as advising CTO, he stepped into the CEO seat to commercialize Pyxis, the company's generative-AI engine for untargeted molecular annotation, and led the company through a 2025 Series A from Lewis & Clark Partners and OMX Ventures.
Keythera Pharmaceuticals Co., Ltd
Keythera (Suzhou) Biopharmaceuticals is a clinical-stage biotech building first-in-class small molecule drugs for cancer and autoimmune disease. Its core edge is ADMS - Affinity Detection by Mass Spectroscopy - an affinity-based high-throughput screening platform that can screen up to 250,000 compounds per day per workstation and fuses bioinformatics, structural chemistry, computer-aided drug design and AI to find and optimize drug candidates faster and at lower risk. Founded in 2020 by industry veteran Dr. Yongqi Deng, the company has built six pipelines, advanced its lead EP4 antagonist KF-0210 into the clinic, and raised roughly RMB 100M in Series A funding.
STORM Therapeutics
STORM Therapeutics is a Cambridge, UK biotechnology company pioneering the field of RNA epigenetics. It designs small-molecule inhibitors of RNA-modifying enzymes to treat cancer and other diseases. Its lead drug, STC-15, is the first RNA-modifying enzyme inhibitor to reach human clinical trials, now in a Phase 2 study for sarcoma.
Andrew Quong
Andrew Quong is President and CEO of InterVenn Biosciences, a South San Francisco-based precision diagnostics company unlocking the human glycoproteome through AI-powered platforms. With a PhD in Physics and over 30 years spanning national laboratories, academia, and biotech, Quong bridges the physical and computational sciences with clinical medicine. He led InterVenn's development of GlycoKnow Ovarian, a non-invasive blood-based liquid biopsy test for distinguishing ovarian cancer from benign masses, and has steered the company through key commercialization milestones including a $201M Series C raise in 2021.